Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 16, 2018

Primary Completion Date

May 1, 2021

Study Completion Date

February 16, 2022

Conditions

Other Infectious Diseases

Interventions

DRUG

Cefepime

Given IV

DRUG

Ceftolozane

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Meropenem

Given IV

DRUG

Piperacillin-Tazobactam

Given IV

DRUG

Tazobactam

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03485950 - Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam | Biotech Hunter | Biotech Hunter